Our findings indicate a specific mechanism driving the abnormal elevation of PCSK9 expression in tumors through epigenetic regulation, which would provide a theoretical basis for targeting tumor PCSK9 expression in cancer immunotherapy. This evidence concerns the gene PCSK9 and cancer.